Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
MDXG's Cash to Debt is ranked higher than
91% of the 323 Companies
in the Global Medical Devices industry.

( Industry Median: 2.59 vs. MDXG: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MDXG' s Cash to Debt Range Over the Past 10 Years
Min: 0.6  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.65
MDXG's Equity to Asset is ranked higher than
75% of the 301 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. MDXG: 0.65 )
Ranked among companies with meaningful Equity to Asset only.
MDXG' s Equity to Asset Range Over the Past 10 Years
Min: 0.44  Med: 0.81 Max: 0.87
Current: 0.65
0.44
0.87
Interest Coverage 167.32
MDXG's Interest Coverage is ranked higher than
64% of the 198 Companies
in the Global Medical Devices industry.

( Industry Median: 53.44 vs. MDXG: 167.32 )
Ranked among companies with meaningful Interest Coverage only.
MDXG' s Interest Coverage Range Over the Past 10 Years
Min: 147.92  Med: 5141.65 Max: 9999.99
Current: 167.32
147.92
9999.99
F-Score: 5
Z-Score: 20.26
M-Score: -1.22
WACC vs ROIC
10.87%
42.40%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 6/10

vs
industry
vs
history
Operating margin (%) 10.80
MDXG's Operating margin (%) is ranked higher than
80% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 1.90 vs. MDXG: 10.80 )
Ranked among companies with meaningful Operating margin (%) only.
MDXG' s Operating margin (%) Range Over the Past 10 Years
Min: -1334.98  Med: -12.13 Max: 13.01
Current: 10.8
-1334.98
13.01
Net-margin (%) 13.28
MDXG's Net-margin (%) is ranked higher than
86% of the 309 Companies
in the Global Medical Devices industry.

( Industry Median: 0.86 vs. MDXG: 13.28 )
Ranked among companies with meaningful Net-margin (%) only.
MDXG' s Net-margin (%) Range Over the Past 10 Years
Min: -1447.4  Med: -17.64 Max: 15.72
Current: 13.28
-1447.4
15.72
ROE (%) 26.43
MDXG's ROE (%) is ranked higher than
96% of the 296 Companies
in the Global Medical Devices industry.

( Industry Median: 1.52 vs. MDXG: 26.43 )
Ranked among companies with meaningful ROE (%) only.
MDXG' s ROE (%) Range Over the Past 10 Years
Min: -276.61  Med: -80.66 Max: 29.85
Current: 26.43
-276.61
29.85
ROA (%) 20.15
MDXG's ROA (%) is ranked higher than
97% of the 325 Companies
in the Global Medical Devices industry.

( Industry Median: -0.71 vs. MDXG: 20.15 )
Ranked among companies with meaningful ROA (%) only.
MDXG' s ROA (%) Range Over the Past 10 Years
Min: -557.14  Med: -59.18 Max: 24.02
Current: 20.15
-557.14
24.02
ROC (Joel Greenblatt) (%) 52.17
MDXG's ROC (Joel Greenblatt) (%) is ranked higher than
92% of the 321 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. MDXG: 52.17 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MDXG' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -2458.54  Med: -847.17 Max: 71.75
Current: 52.17
-2458.54
71.75
Revenue Growth (3Y)(%) 70.80
MDXG's Revenue Growth (3Y)(%) is ranked higher than
99% of the 229 Companies
in the Global Medical Devices industry.

( Industry Median: 3.60 vs. MDXG: 70.80 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MDXG' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: 0  Med: 0.00 Max: 261.7
Current: 70.8
0
261.7
» MDXG's 10-Y Financials

Financials (Next Earnings Date: Est. 2016-07-30)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2015

MDXG Guru Trades in Q1 2015

Steven Cohen 942,500 sh (New)
Paul Tudor Jones 38,800 sh (+103.16%)
Joel Greenblatt 61,414 sh (+70.38%)
Jim Simons 174,400 sh (-12.00%)
» More
Q2 2015

MDXG Guru Trades in Q2 2015

Jim Simons 581,500 sh (+233.43%)
Joel Greenblatt 56,809 sh (-7.50%)
Steven Cohen 834,300 sh (-11.48%)
Paul Tudor Jones 34,200 sh (-11.86%)
» More
Q3 2015

MDXG Guru Trades in Q3 2015

Jim Simons Sold Out
Steven Cohen 822,900 sh (-1.37%)
Paul Tudor Jones 29,700 sh (-13.16%)
Joel Greenblatt 47,930 sh (-15.63%)
» More
Q4 2015

MDXG Guru Trades in Q4 2015

Jim Simons 19,600 sh (New)
Paul Tudor Jones 36,500 sh (+22.90%)
Steven Cohen 908,600 sh (+10.41%)
Joel Greenblatt Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with MDXG

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 31.37
MDXG's P/E(ttm) is ranked lower than
58% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 26.66 vs. MDXG: 31.37 )
Ranked among companies with meaningful P/E(ttm) only.
MDXG' s P/E(ttm) Range Over the Past 10 Years
Min: 28.22  Med: 72.03 Max: 5530
Current: 31.37
28.22
5530
Forward P/E 17.86
MDXG's Forward P/E is ranked higher than
57% of the 51 Companies
in the Global Medical Devices industry.

( Industry Median: 18.69 vs. MDXG: 17.86 )
Ranked among companies with meaningful Forward P/E only.
N/A
PE(NRI) 31.37
MDXG's PE(NRI) is ranked lower than
56% of the 165 Companies
in the Global Medical Devices industry.

( Industry Median: 26.94 vs. MDXG: 31.37 )
Ranked among companies with meaningful PE(NRI) only.
MDXG' s PE(NRI) Range Over the Past 10 Years
Min: 28.11  Med: 73.47 Max: 1843.33
Current: 31.37
28.11
1843.33
Price/Owner Earnings (ttm) 36.39
MDXG's Price/Owner Earnings (ttm) is ranked lower than
62% of the 109 Companies
in the Global Medical Devices industry.

( Industry Median: 30.78 vs. MDXG: 36.39 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
MDXG' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 36.67  Med: 55.03 Max: 930
Current: 36.39
36.67
930
P/B 7.09
MDXG's P/B is ranked lower than
88% of the 295 Companies
in the Global Medical Devices industry.

( Industry Median: 2.93 vs. MDXG: 7.09 )
Ranked among companies with meaningful P/B only.
MDXG' s P/B Range Over the Past 10 Years
Min: 5.63  Med: 10.43 Max: 21.82
Current: 7.09
5.63
21.82
P/S 4.56
MDXG's P/S is ranked lower than
67% of the 291 Companies
in the Global Medical Devices industry.

( Industry Median: 3.18 vs. MDXG: 4.56 )
Ranked among companies with meaningful P/S only.
MDXG' s P/S Range Over the Past 10 Years
Min: 4.56  Med: 11.34 Max: 825
Current: 4.56
4.56
825
PFCF 70.38
MDXG's PFCF is ranked lower than
86% of the 96 Companies
in the Global Medical Devices industry.

( Industry Median: 9999.00 vs. MDXG: 70.38 )
Ranked among companies with meaningful PFCF only.
MDXG' s PFCF Range Over the Past 10 Years
Min: 48.21  Med: 72.90 Max: 187.46
Current: 70.38
48.21
187.46
POCF 45.65
MDXG's POCF is ranked lower than
87% of the 131 Companies
in the Global Medical Devices industry.

( Industry Median: 21.24 vs. MDXG: 45.65 )
Ranked among companies with meaningful POCF only.
MDXG' s POCF Range Over the Past 10 Years
Min: 36.4  Med: 55.35 Max: 1830
Current: 45.65
36.4
1830
EV-to-EBIT 32.04
MDXG's EV-to-EBIT is ranked lower than
69% of the 160 Companies
in the Global Medical Devices industry.

( Industry Median: 21.14 vs. MDXG: 32.04 )
Ranked among companies with meaningful EV-to-EBIT only.
MDXG' s EV-to-EBIT Range Over the Past 10 Years
Min: -618.7  Med: -8.30 Max: 1158.8
Current: 32.04
-618.7
1158.8
EV-to-EBITDA 28.79
MDXG's EV-to-EBITDA is ranked lower than
73% of the 175 Companies
in the Global Medical Devices industry.

( Industry Median: 17.32 vs. MDXG: 28.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDXG' s EV-to-EBITDA Range Over the Past 10 Years
Min: -809.7  Med: -8.80 Max: 994.2
Current: 28.79
-809.7
994.2
Current Ratio 3.60
MDXG's Current Ratio is ranked higher than
65% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.86 vs. MDXG: 3.60 )
Ranked among companies with meaningful Current Ratio only.
MDXG' s Current Ratio Range Over the Past 10 Years
Min: 0.07  Med: 3.61 Max: 14
Current: 3.6
0.07
14
Quick Ratio 3.32
MDXG's Quick Ratio is ranked higher than
70% of the 319 Companies
in the Global Medical Devices industry.

( Industry Median: 2.09 vs. MDXG: 3.32 )
Ranked among companies with meaningful Quick Ratio only.
MDXG' s Quick Ratio Range Over the Past 10 Years
Min: 0.07  Med: 3.32 Max: 14
Current: 3.32
0.07
14
Days Inventory 124.38
MDXG's Days Inventory is ranked higher than
70% of the 286 Companies
in the Global Medical Devices industry.

( Industry Median: 136.13 vs. MDXG: 124.38 )
Ranked among companies with meaningful Days Inventory only.
MDXG' s Days Inventory Range Over the Past 10 Years
Min: 11.88  Med: 121.83 Max: 135.08
Current: 124.38
11.88
135.08
Days Sales Outstanding 98.39
MDXG's Days Sales Outstanding is ranked lower than
74% of the 273 Companies
in the Global Medical Devices industry.

( Industry Median: 70.17 vs. MDXG: 98.39 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDXG' s Days Sales Outstanding Range Over the Past 10 Years
Min: 74.94  Med: 94.12 Max: 104.76
Current: 98.39
74.94
104.76
Days Payable 207.25
MDXG's Days Payable is ranked higher than
75% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 62.81 vs. MDXG: 207.25 )
Ranked among companies with meaningful Days Payable only.
MDXG' s Days Payable Range Over the Past 10 Years
Min: 88.08  Med: 105.51 Max: 164.89
Current: 207.25
88.08
164.89

Valuation & Return

vs
industry
vs
history
Price/Net Current Asset Value 25.10
MDXG's Price/Net Current Asset Value is ranked lower than
76% of the 215 Companies
in the Global Medical Devices industry.

( Industry Median: 6.20 vs. MDXG: 25.10 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
MDXG' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 12.98  Med: 17.86 Max: 135
Current: 25.1
12.98
135
Price/Tangible Book 16.37
MDXG's Price/Tangible Book is ranked lower than
79% of the 266 Companies
in the Global Medical Devices industry.

( Industry Median: 3.89 vs. MDXG: 16.37 )
Ranked among companies with meaningful Price/Tangible Book only.
MDXG' s Price/Tangible Book Range Over the Past 10 Years
Min: 10.2  Med: 16.17 Max: 83.48
Current: 16.37
10.2
83.48
Price/Projected FCF 9.07
MDXG's Price/Projected FCF is ranked lower than
88% of the 118 Companies
in the Global Medical Devices industry.

( Industry Median: 2.08 vs. MDXG: 9.07 )
Ranked among companies with meaningful Price/Projected FCF only.
MDXG' s Price/Projected FCF Range Over the Past 10 Years
Min: 11.29  Med: 19.71 Max: 28.12
Current: 9.07
11.29
28.12
Price/Median PS Value 0.40
MDXG's Price/Median PS Value is ranked higher than
89% of the 246 Companies
in the Global Medical Devices industry.

( Industry Median: 1.04 vs. MDXG: 0.40 )
Ranked among companies with meaningful Price/Median PS Value only.
MDXG' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.5  Med: 0.99 Max: 9
Current: 0.4
0.5
9
Price/Graham Number 4.77
MDXG's Price/Graham Number is ranked lower than
71% of the 178 Companies
in the Global Medical Devices industry.

( Industry Median: 2.14 vs. MDXG: 4.77 )
Ranked among companies with meaningful Price/Graham Number only.
MDXG' s Price/Graham Number Range Over the Past 10 Years
Min: 0.43  Med: 4.16 Max: 154.5
Current: 4.77
0.43
154.5
Earnings Yield (Greenblatt) (%) 3.08
MDXG's Earnings Yield (Greenblatt) (%) is ranked higher than
64% of the 310 Companies
in the Global Medical Devices industry.

( Industry Median: 0.50 vs. MDXG: 3.08 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MDXG' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: 0.1  Med: 1.50 Max: 3.08
Current: 3.08
0.1
3.08

More Statistics

Revenue(Mil) $187
EPS $ 0.27
Beta1.19
Short Percentage of Float19.09%
52-Week Range $6.71 - 13.20
Shares Outstanding(Mil)107.81

Analyst Estimate

Dec16 Dec17 Dec18
Revenue(Mil) 257 312 366
EPS($) 0.33 0.44 0.59
EPS without NRI($) 0.33 0.44 0.59

Business Description

Industry: Medical Devices » Medical Devices
Compare:OISE:OSSRu, XSWX:TECN, NYSE:PEN, OCSE:AMBU B, SHSE:600587, SZSE:300238 » details
Traded in other countries:MXE.Germany,
MiMedx Group Inc was incorporated in Florida on February 28, 2008. The Company develops clinical solutions for the use of its biomaterials to regenerate soft tissue in wound healing, orthopedics and other specialty fields of medicine. It is an integrated developer, manufacturer and marketer of patent protected regenerative biomaterial products and allografts processed from human amniotic membrane. Its biomaterial platform technologies include the device technologies HydroFix and CollaFixM, and its tissue technologies, AmnioFix and EpiFix. It is a supplier of allografts processed from amniotic tissue, having supplied approximately over 200,000 allografts to date for application in the Surgical, Orthopedic, Spinal, Wound Care, Ophthalmic, and Dental segments of healthcare. Its technology and products are Purion, AmnioFix, EpiFix and other Tissue -Based Allografts and Medical Devices- CollaFix and HydroFix. The Company operates a licensed tissue bank. Its solutions are being used to treat chronic wounds, including diabetic foot ulcers, venous stasis ulcers, arterial ulcers and pressure ulcers, burns and surgical wounds.
» More Articles for MDXG

Headlines

Articles On GuruFocus.com
Celleration Acquisition Just the Start of Alliqua’s M&A Strategy Feb 04 2015 

More From Other Websites
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference Apr 28 2016
MiMedx To Present At The 41st Annual Deutsche Bank Securities Healthcare Conference Apr 28 2016
Edited Transcript of MDXG earnings conference call or presentation 26-Apr-16 2:30pm GMT Apr 27 2016
MiMedx Group downgraded by First Analysis Sec Apr 27 2016
MiMedx Group Inc Earnings Call scheduled for 10:30 am ET today Apr 26 2016
Q1 2016 MiMedx Group Inc Earnings Release - Before Market Open Apr 26 2016
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 26 2016
MiMedx Announces First Quarter 2016 Results Apr 25 2016
MiMedx Announces Release Date for 2016 First Quarter Results Apr 19 2016
MiMedx Announces Release Date for 2016 First Quarter Results Apr 19 2016
ETF’s with exposure to MiMedx Group, Inc. : April 13, 2016 Apr 13 2016
The Impact of MiMedx EpiFix® to be Presented at SAWC Conference Apr 12 2016
The Impact of MiMedx EpiFix® to be Presented at SAWC Conference Apr 12 2016
MiMedx Group, Inc. breached its 50 day moving average in a Bearish Manner : MDXG-US : April 12, 2016 Apr 12 2016
Edited Transcript of MDXG earnings conference call or presentation 11-Apr-16 3:00pm GMT Apr 12 2016
What is Going on With These 5 Falling Stocks? Apr 11 2016
MIMEDX GROUP, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial... Apr 11 2016
MiMedx Announces First Quarter of 2016 Revenue Results Apr 10 2016
MiMedx Announces First Quarter of 2016 Revenue Results Apr 10 2016
MiMedx To Present At The 15th Annual Needham Healthcare Conference Apr 05 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK